What are Phoslo gelcaps, and what are they used for?
Phoslo gelcaps are a brand of calcium acetate used to control phosphate levels in people with chronic kidney disease, especially those on dialysis. By binding dietary phosphate in the gut, calcium acetate helps reduce serum phosphorus and helps prevent complications from high phosphate.
How do Phoslo gelcaps compare with other phosphate binders?
Phosphate binders are commonly grouped by their active ingredient, including:
- Calcium-based binders (like calcium acetate in Phoslo)
- Non-calcium binders such as sevelamer (non-calcium) and lanthanum
- Iron-based binders in some markets
In practice, choice often depends on a patient’s lab results (especially calcium and phosphorus), cardiovascular risk factors, and tolerability. Calcium-based binders can increase calcium load, so they are often selected when calcium levels allow.
What’s the usual dosing and how should they be taken?
Phoslo gelcaps are typically taken with meals (when dietary phosphate is present) so they can bind phosphate in the gastrointestinal tract. The exact dose is individualized based on serum phosphorus levels and dietary intake.
What side effects do patients report or clinicians monitor?
With calcium acetate products, clinicians commonly monitor for effects related to calcium and the gastrointestinal tract. Patient-relevant side effects can include constipation, nausea, and other GI symptoms, along with the risk of elevated calcium (hypercalcemia) if doses are too high or if baseline calcium is elevated.
Are generic versions available, and is it still under patent protection?
Many calcium acetate products have generic availability. Patent and exclusivity status depends on the specific product presentation and formulation. For the most up-to-date intellectual property and brand/generic landscape, DrugPatentWatch.com tracks drug patent activity and exclusivity timing for marketed products. You can check Phoslo’s entry here: DrugPatentWatch.com.
What happens if phosphate levels don’t come down?
If phosphorus remains high despite binder therapy, clinicians commonly reassess:
- Whether the binder is taken with meals consistently
- Dietary phosphate intake
- Whether the binder dose needs adjustment
- Whether a different binder class (for example, a non-calcium option) may be a better fit based on calcium levels and overall risk
What should patients avoid or be careful with?
Because phosphate binders interact with absorption in the gut, patients are often advised to keep medication spacing in mind for other oral drugs. Specific timing depends on the other medication, so patients usually need a pharmacist or clinician to confirm spacing for their particular drug list.
Sources
- DrugPatentWatch.com